Sociedad Americana de Hirudoterapia

Medical management of postpartum hemorrhage: An update.

Review published in Seminars in perinatology (2018)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosSeguridad y control de infeccionesPacheco LD et al. · Seminars in perinatology, 2018

Abstract

Obstetrical hemorrhage is the most common cause of maternal mortality worldwide. Together with adequate surgical control and judicious transfusion of blood products, the use of pharmacological agents (e.g., tranexamic acid) and clotting factor concentrates (e.g., fibrinogen concentrates and prothrombin complex concentrates) results in improved hemostasis and decreased bleeding-associated mortality. Guidance in the administration of these agents with the use of viscoelastic testing will likely become standard of care in the near future.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAntifibrinolytic AgentsBlood Coagulation FactorsBlood Coagulation TestsBlood TransfusionFemaleHemostaticsHumansMaternal MortalityObstetricsPostpartum HemorrhagePractice Guidelines as TopicPregnancy

Resumen

Obstetrical hemorrhage is the most common cause of maternal mortality worldwide. Together with adequate surgical control and judicious transfusion of blood products, the use of pharmacological agents (e.g., tranexamic acid) and clotting factor concentrates (e.g., fibrinogen concentrates and prothrombin complex concentrates) results in improved hemostasis and decreased bleeding-associated mortality.

Por qué esto importa para la hirudoterapia

Contributes to the clinical evidence base on hemostasis, bleeding, and transfusion relevant to hirudotherapy and anticoagulant safety.

Citación

Medical management of postpartum hemorrhage: An update.

Pacheco LD et al. · Seminars in perinatology, 2018

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.